Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Methylxanthine probably leads to lower major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower failed extubation compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower any apneic episodes compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower failed apnea reduction compared with placebo or control (moderate certainty).
Methylxanthine may leads to lower positive‐pressure ventilation after institution of treatment compared with placebo or control (low certainty).
Methylxanthine leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (high certainty).
It is very uncertain whether methylprednisolone plus azathioprine changes mortality at 1 year compared with methylprednisolone plus dapsone (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether betamethasone acetate plus phosphate changes any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
It is very uncertain whether betamethasone acetate plus phosphate changes respiratory distress syndrome compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
It is very uncertain whether betamethasone acetate plus phosphate changes intraventricular haemorrhage compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).